---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-26-000025"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2026-07-30T10:15:42+00:00"
generated_at: "2026-07-30T10:20:20.172635+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amneal Q2 net revenue $796M (+10% YoY); GAAP EPS $0.18; raises FY 2026 guidance

## Summary
- Net revenue $796M (+10% YoY); GAAP net income $58M, diluted EPS $0.18 (vs $0.07 YoY).
- Adjusted EBITDA $206M (+12% YoY); adjusted diluted EPS $0.30 (+20% YoY).
- Specialty revenue +17% driven by CREXONT, BREKIYA, UNITHROID; Affordable Medicines +13% on complex portfolio.
- Raising full-year 2026 guidance for second time this year; debt repricing in July reduces interest cost.
- Pending Kashiv transaction to establish biosimilars as new growth vertical.

## SEC filing metadata
- accession: 0001723128-26-000025
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2026-07-30T10:15:42+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/0001723128-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-26-000025
- JSON: https://secwatch.observer/filing/0001723128-26-000025.json
- Plain text: https://secwatch.observer/filing/0001723128-26-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.